Post expires at 12:16pm on Friday May 15th, 2015
Tags: 1st line chemotherapy, AFP, ALK-related malignancies, AllergoOncology, Androgen Receptor, Anemia, anti-angiogenic, anti-cancer stem cell, Antiandrogens, Apoptosis, apoptosis; kinase; leukemia; Mcl-1, Aspirin, astrocytoma genetics, Awareness, BCR-ABL, beta-catenin, Beta-Tubulin isotypes, bevacizumab, biomarker, biomarker discovery, biotherapeutics, body image, BRAF, BRCA1, BRCA2, breast, breast cancer, Breast cancer intraoperative radiotherapy, Bronchoscopy, CA-125, CA19.9, Cancer, cancer cure, cancer screening registry, Cancer stem cells, cancerawareness, carcinogen, Catration-Resistant Prostate Cancer, CD44, CEA, cell wall binding, cell wall teichoic acid, cell-mediated immunotherapy, cervical cancer screening, chemoprevention, Chemorx, chemotherapy, Chimeric antigen receptor ErbB family, chromatin remodelling, Chronic Myeloid Leukemia, colorectal cancer, communication, Comprehensive Geriatric Assessment, contraception, CT scanning, Cytopathology, diagnosis, drug resistance, drugresistance, e-health, early detection, Early diagnosis, EGFR, Elderly, endobronchial ultrasound, Endolysin, epidemiology, epigenetic, Epigenetic markers of progression and treatment response in breast cancer, Epigenetics, ErbB receptors, exposure, fertility, FKBPL, fluorophores, FOLFIRI, Gastrointestinal stromal tumor, glioblastoma, head and neck, HER-2, IgE, IgG, immunochemical test, Immunotherapy, Intraoperative Radiation, Intravenous, Iron, KIT, leukemia, linac, Liver Cancer, lung cancer, mAb effector functions, Macrophages, mammography, mammography early detection of breast cancer, MCAD campaign, Melanoma, metastatic CRC, Microtubule Targeting Chemotherapy, minimal residual disease, molecular targeted therapies, Monocytes/macrophages, Mouth Head and Neck Cancer, MRM3, murine models, Non-small-cell lung carcinoma, NSCLC, Nucleosomes, Oncogenes, oncology, optical diagnosis, Ovarian Cancer, over-diagnosis, overdiagnosis, paediatric lymphoma, Pancreatic Cancer, Pap smear, participation rate and screening, peptide therapeutic, personalised medicine, pre-malignancies, PRM, prophylaxis, prostate cancer, Prostate Specific Antigen, proteomics, PSA, Psychosocial Support, quality control, Radiation Therapy, radioisotopes, Reprodutive health, Rhabdoid coloretal tumors, risk, risk assesment, risk stratification, risk-benefit, S100, Sarcoma, screen, screening., second line, signal transduction, singl test, Skyline, Solid tumours, SRM/MRM, Staging, survival, tail fibre, targeted screening, TAT, therapeutic, TKI, TMT 10-plex, transciption, Trastuzumab, treatment, two consecutive test, tyrosine kinase inhibitors, V600E, Vitamin D, Whole exome sequencing, Wnt signalling, young adults
This site is regularly updated with information regarding the one day Life Science events within the UK run by Euroscicon
Recent Meeting Reports
- 3rd International Forum for Disaster Victim Identification
- The 2014 Controlling Cancer Summit Anti-Cancer Therapeutics
- The Immunology of Ageing
- 2014 Ageing summit: Establishing anti-ageing medicines
- The Immunology of a Successful Pregnancy
- Analysis of Autophagy Regulation: Discussion of recent research and new technologies
- The 2013 Stem Cells Discussion Forum: Working Towards Clinical Application
- Induced Pluripotent Stem Cells: Production and Utility in Regenerative Medicine and Other Applications
- Towards 2020 the genetic influence on obesity and associated disease
- Cell suicide is not painless for the flow cytometrist: New assays to measure cell death
Life Science Events is Part of Euroscicon Ltd. Registered in England and Wales, Company number: 4326921, Trading Address: Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK. Registered Office: 47 High Street, High Barnet, EN5 5UW
Magazine Flow created by Themes by bavotasan.com.
Magazine Flow created by Themes by bavotasan.com.
Follow Us!